Text descriptions and footnotes for the monitoring and evaluation of colorectal cancer screening quality indicators report

Key statistics on colorectal cancer screening

The burden of colorectal cancer in Canada (infographic)

This infographic in the monitoring and evaluation of colorectal cancer screening quality indicators report shows key statistics about colorectal cancer from 2019.

• Colorectal cancer is the third most diagnosed cancer in Canada and is the second leading cause of death from cancer.
• The lifetime probability of developing colorectal cancer is 6.3%. The lifetime probability of dying from colorectal cancer is 2.9%.
• It is estimated that in 2019, 26300 people were diagnosed with colorectal cancer (72 per day) and 9500 people died of colorectal cancer (26 per day).

Canada age-standardized incidence rate by age (50-64 and 65+), 2009 – 2018

This graph shows the age-standardized incidence rate of colorectal cancer in Canada for people aged 50 to 64 years old between 2009 and 2018 as follows:

• 2009: 87 per 100,000 people
• 2010: 85 per 100,000 people
• 2011: 85 per 100,000 people
• 2012: 85 per 100,000 people
• 2013: 82 per 100,000 people
• 2014: 85 per 100,000 people
• 2015: 83 per 100,000 people
• 2016: 80 per 100,000 people
• 2017: 76 per 100,000 people
• 2018: 75 per 100,000 people

For people older than 65 years old, the age-standardized incidence rate of colorectal cancer between 2009 and 2018 was as follows:

• 2009: 291 per 100,000 people
• 2010: 292 per 100,000 people
• 2011: 290 per 100,000 people
• 2012: 279 per 100,000 people
• 2013: 280 per 100,000 people
• 2014: 271 per 100,000 people
• 2015: 265 per 100,000 people
• 2016: 244 per 100,000 people
• 2017: 234 per 100,000 people
• 2018: 223 per 100,000 people

Footnote

• Data includes all jurisdictions except Quebec.

Canada age-standardized incidence rate by age, 2018

This graph shows the age-standardized incidence rate of colorectal cancer in Canada for different age groups in 2018 as follows:

• Age 20 to 29: 3 per 100,000
• Age 30 to 29: 9 per 100,000
• Age 40 to 44: 19 per 100,000
• Age 45 to 49: 33 per 100,000
• Age 50-64: 75 per 100,000
• Older than 65 years old: 223 per 100,000

Footnote

• Data includes all jurisdictions except Quebec.

Participation rate

Population-based participation rates for fecal tests (in 30 months) among individuals, by jurisdiction, January 1, 2017 – June 30, 2019

This graph shows the participation rate for fecal tests by jurisdiction as follows:

• Alberta: 45%
• Saskatchewan: 55%
• Manitoba: 38%
• Ontario: 35%
• Quebec: 42%
• New Brunswick: 18%
• Nova Scotia: 37%
• Prince Edward Island: 27%
• Newfoundland and Labrador: 26%
• Yukon: 31%
• Northwest Territories: 27%

The target is shown at 60%.

Footnotes

• Data is not available for BC and NU.
• SK: Opportunistic screening is included in this analysis.
• MB: Data includes program FOBTs that had a successful result and non-program FOBTs where the result is unknown and are assumed to be successful. The numerator includes a subset of fecal tests completed in the province (those for which data is available).
• ON: Individuals were considered screen eligible if they were 50-74 years old without a prior colorectal cancer or prior total colectomy or those who have not had colonoscopy and/or flex sigmoidoscopy within 10 years before Jan 1, 2017. ‘Successful FTs’ contains ‘successful positive’ and ‘successful negative’ results as well as ‘unknown’ results identified through the OHIP claims database.
• QC: Data reflects opportunistic screening only as the screening program was not implemented yet. Source of the screen-eligible denominator is the population projections of 2011-2036 (series produced in November 2014) by the Institut de la statistique du Québec.
• NB: The colon cancer screening program was not fully implemented province-wide during this reporting period.
• NL: The screening program has a self/provider-based referral system.
• YT: Screen eligible population for each age group is the average population of 2017 and 2018 from the Yukon Bureau of Statistics.
• NT: Screen-eligible denominator is the July 2018 population estimates from NWT Bureau of Statistics.

Data source: Provincial and territorial cancer agencies and programs

Population-based participation rates for fecal tests (in 30 months), by age group and sex, jurisdictions combined, January 1, 2017 – June 30, 2019

This graph shows the participation rate for fecal tests in all jurisdictions combined by age group and sex. For all sexes, the participation rate is as follows:

• Age 50 to 74: 39%
• Age 50 to 54: 29%
• Age 55 to 59: 36%
• Age 60 to 64: 43%
• Age 65 to 69: 46%
• Age 70 to 74: 49%

For males, the participation rate is as follows:

• Age 50 to 74: 37%
• Age 50 to 54: 27%
• Age 55 to 59: 33%
• Age 60 to 64: 41%
• Age 65 to 69: 45%
• Age 70 to 74: 49%

For females, the participation rate is as follows:

• Age 50 to 74: 41%
• Age 50 to 54: 32%
• Age 55 to 59: 38%
• Age 60 to 64: 45%
• Age 65 to 69: 47%
• Age 70 to 74: 49%

The target is shown at 60%.

Footnotes

• Data include AB, SK, MB, ON, QC, NB, NS, PE, NL, YT and NT.

Data source: Provincial and territorial cancer agencies and programs

Invitation-based participation rates for fecal tests (in 30 months) among individuals, by jurisdiction, January 1, 2017 – December 31, 2018

This graph shows the invitation-based participation rate for fecal tests by jurisdiction as follows:

• Alberta: Data not available
• Saskatchewan: 49%
• Manitoba: 49%
• Ontario: Data not available
• Quebec: Data not available
• New Brunswick: 22%
• Nova Scotia: 37%
• Prince Edward Island: 14%
• Newfoundland and Labrador: Data not available
• Yukon: 76%
• Northwest Territories: Data not available

Footnotes

• Data is not available for BC, AB, ON, QC, NL, NT and NU.
• MB: Age is calculated at the date of the first successful FOBT analyzed in the 30-month time period. For individuals with no successful FOBT in the 30-month time period, age is calculated at the date the first invitation was mailed within the 2-year time period.
• NB: The colon cancer screening program was not fully implemented province-wide during this reporting period.
• PE: Population-based invitation in place. The invitation addresses Islanders who do not have a FIT screening history and are new to PEI (age 50 to 74) or recently turned 50, 55, 60, 65, or 70. About 18% of mail invitations are returned to the program due to an invalid address. 
• YT: There is no population wide invitation process due to available capacity. The numbers of invited males and females from Jan 1, 2017 to Dec 31, 2018 are estimated to be higher, meaning health care providers invited more people to the program but were not captured successfully resulting in a higher participation rate.

Data source: Provincial and territorial cancer agencies and programs

Percentage of overdue for colorectal cancer screening among individuals aged 50-74, by jurisdiction, 2018

This graph shows the percentage of people who are overdue for colorectal cancer screening by jurisdiction as follows:

• Alberta: Data not available
• Saskatchewan: Data not available
• Manitoba: 46%
• Ontario: 37%
• Quebec: Data not available
• New Brunswick: Data not available
• Nova Scotia: Data not available
• Prince Edward Island: 40%
• Newfoundland and Labrador: Data not available
• Yukon: 77%
• Northwest Territories: Data not available.

Footnotes

• Data is not available for BC, AB, SK, QC, NB, NS, NL, NT and NU.
• MB: An individual was considered ineligible and was excluded from the calculation if any of the following occurred: (1) A death date prior to the end of 2018; (2) Cessation of provincial health coverage prior to the end of 2018; (3) A cancer diagnosis prior to the end of 2018; (4) Their demographic record did not exist in the ColonCheck registry until after December 31, 2018; (5) They opted out of participation in ColonCheck.
• ON: Individuals with a missing/invalid Health Insurance Number, date of birth or non-Ontario residents are excluded. Individuals were considered ‘Screen eligible’ if they were 50-74 as of Jan 1, of 2018, with no colorectal cancer and total colectomy prior to Jan 1, 2018.
• PE: Data is for 2019. An individual was considered overdue if they did not have a FIT test in the previous two and a half years, or a colonoscopy or sigmoidoscopy in the previous 10 years. Individuals with colorectal cancers were removed. Data may contain diagnostic tests for symptomatic people.
• YT: Eligible population is estimated from the Yukon Bureau of Statistics December 31, 2018. Overdue Population is the eligible population counts minus the number of patients who had a FIT test in the previous 2 years AND those who had a colonoscopy or sigmoidoscopy in the last 10 years.

Data source: Provincial and territorial cancer agencies and programs

Follow-up colonoscopy rate

Percentage of colonoscopy uptake within 180 days of abnormal fecal tests among individuals aged 50-74, by jurisdiction, screening year 2017 to 2018

This graph shows the percentage of colonoscopy uptake after an abnormal fecal test by jurisdiction as follows:

• Alberta: 70%
• Saskatchewan: 81%
• Manitoba: 87%
• Ontario: 82%
• Quebec: Data not available
• New Brunswick: 84%
• Nova Scotia: 61%
• Prince Edward Island: 81%
• Newfoundland and Labrador: 96%
• Yukon: 65%
• Northwest Territories: Data not available.

The target is shown at 85%.

Footnotes

• Data is not available for BC, QC, NT and NU.
• AB: FT data were extracted from Alberta Colorectal Cancer Screening Program database. Colonoscopy data were extracted from Alberta NACRS/DAD and Physician Claims database.
• SK: Sigmoidoscopy is not included in this analysis. Opportunistic screening is included in  this analysis.
• ON: Includes individuals with an abnormal fecal test between Jan 2017 and June 2019. Colonoscopy was counted within 183 days of an abnormal fecal test result.
• NB: The colon cancer screening program was not fully implemented province-wide during this reporting period. This indicator includes individuals who opted out of  the program/colonoscopy.

Data source: Provincial and territorial cancer agencies and programs

Wait time to follow-up colonoscopy

Percentage of people who have colonoscopies performed within 60 days of abnormal fecal tests among individuals aged 50-74, by jurisdiction, screening year 2017 – 2018

This graph shows the percentage of colonoscopies performed within 60 days of an abnormal fecal test by jurisdiction as follows:

• Alberta: 40%
• Saskatchewan: 69%
• Manitoba: 64%
• Ontario: 66%
• Quebec: Data not available
• New Brunswick: 54%
• Nova Scotia: 26%
• Prince Edward Island: 33%
• Newfoundland and Labrador: 77%
• Yukon: 11%
• Northwest Territories: Data not available

A target line is shown at 90%.

Footnotes

• Data is not available for BC, QC, NT and NU.
• AB: FT data were extracted from Alberta Colorectal Cancer Screening Program database. Colonoscopy data were extracted from Alberta NACRS/DAD and Physician Claims database.
• SK: Sigmoidoscopy is not included in this analysis. Opportunistic screening is included in this analysis.
• MB: The denominator includes only the colonoscopies done within the screening program, while the numerator includes colonoscopies done within or outside of the screening program.
• ON: Includes individuals with an abnormal fecal test between Jan 2017 and June 2019. Colonoscopy within 60 days was counted among those who had a colonoscopy within 183 days of an abnormal fecal test result.
• NB: The colon cancer screening program was not fully implemented province-wide during this reporting period. This indicator includes individuals who opted out of the program/colonoscopy.

Data source: Provincial and territorial cancer agencies and programs

Wait time (days) from abnormal fecal test to colonoscopy among individuals aged 50-74, by jurisdiction, screening year 2017 – 2018

This graph shows the number of days from an abnormal fecal test to a colonoscopy for the median and 90^th percentile by jurisdiction as follows:

• Alberta:
  • Median: 69 days
  • 90^th percentile: 133 days
• Saskatchewan:
  • Median: 42 days
  • 90^th percentile: 106 days
• Manitoba:
  • Median: 47 days
  • 90^th percentile: 104 days
• Ontario:
  • Median: 46 days
  • 90^th percentile: 105 days
• Quebec:
  • Median: Data not available
  • 90^th percentile: Data not available
• New Brunswick:
  • Median: 56 days
  • 90^th percentile: 106 days
• Nova Scotia:
  • Median: 86 days
  • 90^th percentile: 160 days
• Prince Edward Island:
  • Median: 79 days
  • 90^th percentile: 143 days
• Newfoundland and Labrador:
  • Median: 33 days
  • 90^th percentile: 85 days
• Yukon:
  • Median: 98 days
  • 90^th percentile: 154 days
• Northwest Territories:
  • Median: data not available
  • 90^th percentile: data not available

A target line is shown at 60 days.

Footnotes

• Data is not available for BC, QC, NT and NU.
• AB: FT data were extracted from Alberta Colorectal Cancer Screening Program database. Colonoscopy data were extracted from Alberta NACRS/DAD and Physician Claim database.
• SK: Sigmoidoscopy is not included in this analysis. Opportunistic screening is included in this analysis.
• MB: Data included colonoscopies done within or outside of the screening program.
• ON: Includes individuals with an abnormal fecal test between Jan 2017 and June 2019. Colonoscopy was counted within 183 days of an abnormal fecal test result.
• NB: The colon cancer screening program was not fully implemented province-wide during this reporting period. This indicator includes individuals who opted out of the program/colonoscopy.

Data source: Provincial and territorial cancer agencies and programs

Program invasive colorectal cancer rate

Detection rate (per 1,000) of invasive colorectal cancers through programmatic screening among individuals aged 50-74, by jurisdiction, screening year 2016 – 2017

This graph shows the number of invasive colorectal cancers detected per 1000 screens by jurisdiction as follows:

• Alberta: 2.3 per 1000
• Saskatchewan: 2 per 1000
• Manitoba: 1.1 per 1000
• Ontario: 1.5 per 1000
• Quebec: Data not available
• New Brunswick: 2.3 per 1000
• Nova Scotia: 1.5 per 1000
• Prince Edward Island: 3.5 per 1000
• Newfoundland and Labrador: 5.4 per 1000
• Yukon: Data not available
• Northwest Territories: Data not available

A target line is shown at 2.0 per 1000.

Footnotes

• Data is not available for BC, QC, YT, NT and NU.
• SK: Opportunistic screening is included in this analysis.
• ON: Invasive colorectal cancer was identified as: ICD-O-3 codes C18.0, C18.2-C18.9, C19.9, C20.9, , a morphology indicative of colorectal cancer, microscopically confirmed with a path report. Excluding histology codes: 9590-9989, 8240-8246, 8248-8249. 

Data source: Provincial and territorial cancer agencies and programs

Detection rate (per 1,000) of invasive colorectal cancers through programmatic screening among individuals aged 50-74, by jurisdiction and sex, screening year 2016 – 2017

This graph shows the number of colorectal cancers detected per 1000 screens by jurisdiction and sex as follows:

• Alberta:
  • All sexes: 2.3 per 1000
  • Male: 2.8 per 1000
  • Female: 1.7 per 1000
• Saskatchewan:
  • All sexes: 2.0 per 1000
  • Male:2.7 per 1000
  • Female:1.4 per 1000
• Manitoba:
  • All sexes: 1.1 per 1000
  • Male: 1.5 per 1000
  • Female: 0.9 per 1000
• Ontario:
  • All sexes: 1.5 per 1000
  • Male: 2.0 per 1000
  • Female: 1.0 per 1000
• Quebec:
  • All sexes: No data available
  • Male: No data available
  • Female: No data available
• New Brunswick:
  • All sexes: 2.3 per 1000
  • Male: 2.8 per 1000
  • Female: 1.9 per 1000
• Nova Scotia:
  • All sexes: 1.5 per 1000
  • Male: 1.7 per 1000
  • Female: 1.3 per 1000
• Prince Edward Island:
  • All sexes: 3.5 per 1000
  • Male: 4.1 per 1000
  • Female: 2.9 per 1000
• Newfoundland and Labrador:
  • All sexes: 5.4 per 1000
  • Male: 6.8 per 1000
  • Female: 4.3 per 1000
• Yukon:
  • All sexes: No data available
  • Male: No data available
  • Female: No data available
• Northwest Territories:
  • All sexes: No data available
  • Male: No data available
  • Female: No data available

A target line is shown at 2.0 per 1000.

Footnotes

• Data is not available for BC, QC, YT, NT and NU.
• SK: Opportunistic screening is included in this analysis.
• ON: Invasive colorectal cancer was identified as: ICD-O-3 codes C18.0, C18.2-C18.9, C19.9, C20.9, a morphology indicative of colorectal cancer, microscopically confirmed with a path report. Excluding histology codes: 9590-9989, 8240-8246, 8248-8249

Data source: Provincial and territorial cancer agencies and programs

Detection rate (per 1,000) of invasive colorectal cancers through programmatic screening among individuals aged 50-74, by jurisdiction and age group, screening year 2016 – 2017

This graph shows the number of colorectal cancers detected per 1000 screens by jurisdiction and age group as follows:

• Alberta:
  • 50 to 54: 1.4 per 1000
  • 55 to 59: 1.9 per 1000
  • 60 to 64: 2.2 per 1000
  • 65 to 69: 3.0 per 1000
  • 70 to 74: 3.9 per 1000
• Saskatchewan:
  • 50 to 54: 1.4 per 1000
  • 55 to 59: 1.4 per 1000
  • 60 to 64: 1.7 per 1000
  • 65 to 69: 3.0 per 1000
  • 70 to 74: 2.9 per 1000
• Manitoba:
  • 50 to 54: 0.7 per 1000
  • 55 to 59: Data not available
  • 60 to 64: 0.7 per 1000
  • 65 to 69: 2.0 per 1000
  • 70 to 74: 1.8 per 1000
• Ontario:
  • 50 to 54: 0.7 per 1000
  • 55 to 59: 0.9 per 1000
  • 60 to 64: 1.5 per 1000
  • 65 to 69: 2.0 per 1000
  • 70 to 74: 2.7 per 1000
• Quebec:
  • 50 to 54: Data not available
  • 55 to 59: Data not available
  • 60 to 64: Data not available
  • 65 to 69: Data not available
  • 70 to 74: Data not available
• New Brunswick:
  • 50 to 54: Data not available
  • 55 to 59: 1.1 per 1000
  • 60 to 64:2.5 per 1000
  • 65 to 69: 1.5 per 1000
  • 70 to 74: 4.8 per 1000
• Nova Scotia:
  • 50 to 54: 0.9 per 1000
  • 55 to 59: 1.0 per 1000
  • 60 to 64: 1.1 per 1000
  • 65 to 69: 1.4 per 1000
  • 70 to 74: 2.9 per 1000
• Prince Edward Island:
  • 50 to 54: Data not available
  • 55 to 59: 2.6 per 1000
  • 60 to 64: 2.7 per 1000
  • 65 to 69: 5.0 per 1000
  • 70 to 74: 4.2 per 1000
• Newfoundland and Labrador:
  • 50 to 54: 2.7 per 1000
  • 55 to 59: 6.2 per 1000
  • 60 to 64: 1.8 per 1000
  • 65 to 69: 9.5 per 1000
  • 70 to 74: 11.4 per 1000
• Yukon:
  • 50 to 54: Data not available
  • 55 to 59: Data not available
  • 60 to 64: Data not available
  • 65 to 69: Data not available
  • 70 to 74: Data not available
• Northwest Territories:
  • 50 to 54: Data not available
  • 55 to 59: Data not available
  • 60 to 64: Data not available
  • 65 to 69: Data not available
  • 70 to 74: Data not available

A target line is shown at 2.0 per 1000.

Footnotes

• Data not available for BC, QC, YT, NT and NU.
• SK: Opportunistic screening is included in this analysis.
• MB: Data for age group 60-64 were combined with data for age group 55-59.
• ON: Invasive colorectal cancer was identified as: ICD-O-3 codes C18.0, C18.2-C18.9, C19.9, C20.9, a morphology indicative of colorectal cancer, microscopically confirmed with a path report. Excluding histology codes: 9590-9989, 8240-8246, 8248-8249
• NB: Data for age group 55-59 were combined with data for age group 50-54.
• PE: Data for age group 55-59 were combined with data for age group 50-54.

Data source: Provincial and territorial cancer agencies and programs

Detection rate (per 1,000) of invasive colorectal cancers through programmatic screening among individuals aged 50-74, by jurisdiction and first or subsequent fecal test, screening year 2016 – 2017

This graph shows the number of colorectal cancers detected per 1000 screens by jurisdiction and first or subsequent fecal test as follows:

• Alberta:
  • All fecal tests: 2.3 per 1000
  • First fecal tests: 3.4 per 1000
  • Subsequent fecal tests: 1.7 per 1000
• Saskatchewan:
  • All fecal tests: 2.0 per 1000
  • First fecal tests: 4.2 per 1000
  • Subsequent fecal tests: 1.2 per 1000
• Manitoba:
  • All fecal tests: 1.1 per 1000
  • First fecal tests: 1.4 per 1000
  • Subsequent fecal tests: 0.9 per 1000
• Ontario:
  • All fecal tests: 1.5 per 1000
  • First fecal tests: Data not available
  • Subsequent fecal tests: Data not available
• Quebec:
  • All fecal tests: Data not available
  • First fecal tests: Data not available
  • Subsequent fecal tests: Data not available
• New Brunswick:
  • All fecal tests: 2.3 per 1000
  • First fecal tests: Data suppressed due to small numbers
  • Subsequent fecal tests: Data suppressed due to small numbers
• Nova Scotia:
  • All fecal tests: 1.5 per 1000
  • First fecal tests: 2.1 per 1000
  • Subsequent fecal tests: 1.2 per 1000
• Prince Edward Island:
  • All fecal tests: 3.5 per 1000
  • First fecal tests: 5.4 per 1000
  • Subsequent fecal tests: 1.6 per 1000
• Newfoundland and Labrador:
  • All fecal tests: 5.4 per 1000
  • First fecal tests: 7.4 per 1000
  • Subsequent fecal tests: 1.3 per 1000
• Yukon:
  • All fecal tests: Data not available
  • First fecal tests: Data not available
  • Subsequent fecal tests: Data not available
• Northwest Territories:
  • All fecal tests: Data not available
  • First fecal tests: Data not available
  • Subsequent fecal tests: Data not available

The target is shown at 2.0 per 1000.

Footnotes

• Data not available for BC, QC, YT, NT and NU
• *Data suppressed due to small numbers
• SK: Opportunistic screening is included in this analysis.
• ON: Invasive colorectal cancer was identified as: ICD-O-3 codes C18.0, C18.2-C18.9, C19.9, C20.9, a morphology indicative of colorectal cancer, microscopically confirmed with a path report. Excluding histology codes: 9590-9989, 8240-8246, 8248-8249

Data source: Provincial and territorial cancer agencies and programs

Colorectal cancer stage distribution

Distribution of stage for invasive colorectal cancers detected through programmatic screening among individuals aged 50-74, by jurisdiction, screening year 2016 – 2017

This graph shows the distribution of stage for invasive colorectal cancers detected through programmatic screening by jurisdiction as follows:

• Alberta:
  • Stage 1: 37%
  • Stage 2: 20%
  • Stage 3: 30%
  • Stage 4: 13%
• Saskatchewan:
  • Stage 1: 37%
  • Stage 2: 24%
  • Stage 3: 27%
  • Stage 4: 12%
• Manitoba:
  • Stage 1: 33%
  • Stage 2: 32%
  • Stage 3 and 4 combined: 35%
• Ontario:
  • Stage 1: 30%
  • Stage 2: 26%
  • Stage 3: 35%
  • Stage 4: 9%
• Quebec:
  • Stage 1: Data not available
  • Stage 2: Data not available
  • Stage 3: Data not available
  • Stage 4: Data not available
• New Brunswick:
  • Stage 1: 38%
  • Stage 2: 22%
  • Stage 3: 26%
  • Stage 4: 14%
• Nova Scotia:
  • Stage 1: 48%
  • Stage 2: 18%
  • Stage 3: 30%
  • Stage 4: 4%
• Prince Edward Island:
  • Stage 1 and 2 combined: 63%
  • Stage 3: 19%
  • Stage 4: 19%
• Newfoundland and Labrador:
  • Stage 1: 48%
  • Stage 2: 23%
  • Stage 3 and 4 combined: 29%
• Yukon:
  • Stage 1: Data not available
  • Stage 2: Data not available
  • Stage 3: Data not available
  • Stage 4: Data not available
• Northwest Territories:
  • Stage 1: Data not available
  • Stage 2: Data not available
  • Stage 3: Data not available
  • Stage 4: Data not available

Footnotes

• Data not available for BC, QC, YT, NT and NU.
• AB: Cancer stage groups were defined by AJCC 7th for 2016-2017. From 2018 and onward, cancer stage groups were defined by AJCC 8th.
• SK: Opportunistic screening is included in this analysis.
• MB: Data for Stage III and Stage IV were combined due to small number. Cases diagnosed prior to 2018 were staged using AJCC7, cases diagnosed in 2018 onwards were staged using AJCC8.
• ON: Staging data based on date of diagnosis.
• PE: Data for Stage I and Stage II were combined due to small numbers.
• NL: Data for Stage III and Stage IV were combined due to small numbers.

Data source: Provincial and territorial cancer agencies and programs

Distribution of stage for invasive colorectal cancers detected through programmatic screening among individuals aged 50-74, jurisdictions combined, by first or subsequent fecal test, screening year 2016 – 2017

This graph shows the distribution of stage for invasive colorectal cancers detected through programmatic screening for all jurisdictions combined by first or subsequent fecal test as follows:

• All fecal tests:
  • Stage 1: 39%
  • Stage 2: 21%
  • Stage 3: 29%
  • Stage 4: 11%
• First fecal tests:
  • Stage 1: 36%
  • Stage 2: 20%
  • Stage 3: 31%
  • Stage 4: 13%
• Subsequent fecal tests:
  • Stage 1: 43%
  • Stage 2: 22%
  • Stage 3: 27%
  • Stage 4: 8%

Footnotes

• Data include AB, SK, NB, NS, PE and NL.
• Some totals are less or more than 100% due to rounding.

Data source: Provincial and territorial cancer agencies and programs

14-day post colonoscopy hospitalization rate for perforation or bleeding

Rate (per 1,000) of hospitalization for outpatient colonoscopies, Ontario, by reason for hospitalization, colonoscopies performed from 2017 – 2018

This infographic shows that for every 1,000 people who receive a colonoscopy in Ontario, 0.3 people were admitted to the hospital due to perforation and 2.9 people were admitted to the hospital due to bleeding.

Footnotes

• ON: Hospitalization due to perforation was calculated based on people admitted to hospital within 7 days of their outpatient colonoscopies among individuals age 18+. Hospitalization due to bleeding was calculated based on people admitted within 14 days of their outpatient colonoscopies among individuals age 50+, where at least 1 polyp(s) was removed in the reporting period.

Data source: Provincial and territorial cancer agencies and programs

Interval cancers

Rate (per 1,000) of interval colorectal cancers within 24 months of fecal tests with normal result among individuals aged 50-74, by jurisdiction, fecal tests from 2014 – 2015

This graph shows the rate of interval colorectal cancers after a normal fecal test by jurisdiction as follows:

• Alberta: 0.8 per 1000
• Saskatchewan: 0.7 per 1000
• Manitoba: 1.3 per 1000
• Ontario: Data not available
• Quebec: Data not available
• New Brunswick: Data not available
• Nova Scotia: 1.0 per 1000
• Prince Edward Island: 3.2 per 1000
• Newfoundland and Labrador: Data not available
• Yukon: Data not available
• Northwest Territories: Data not available

Footnotes

• Data not available for BC, ON, QC, NB, NL, YT, NT and NU.
• SK: Opportunistic screening is included in this analysis.
• MB: Age is calculated at the date of the last negative FT analyzed in 2014-2015.

Data source: Provincial and territorial cancer agencies and programs

Rate (per 1,000) of interval colorectal cancers within 6-36 months since normal colonoscopy, among individuals aged 50-74, Saskatchewan and Prince Edward Island combined, fecal tests from 2012 – 2013

This infographic shows that there are 3.0 interval cancers per 1,000 normal colonoscopies within 6-36 months since normal colonoscopy.

Footnote

• Data include SK and PE, combined.

Data source: Provincial and territorial cancer agencies and programs